Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of induction pemetrexed-cisplatin ± bevacizumab vs pemetrexed-cisplatin with concurrent radiotherapy followed by surgery in stage IIIA-N2 non-squamous NSCLC
jRCTs031180402Phase 2Completed
- Start
- Feb 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of pemetrexed, cisplatin and bevacizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms). Primary endpoint: 2-year progression-free survival. Started Feb 2014; status: completed.
02
Drugs
pemetrexedcisplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on jRCTs031180402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180402.